Even those PEPFAR programs operating must limit distribution of preventive medication, according to apparent State Department ...

Iterum Therapeutics (($ITRM)) has held its Q4 earnings call. Read on for the main highlights of the call. During Iterum Therapeutics’ latest ...

The pharmaceutical giant named Jeffrey Legos the head of a division it is counting on to overcome investor pressure and grow ...

Kevin Koch, the President and CEO of Edgewise Therapeutics , Inc. (NASDAQ:EWTX), a biotechnology company with a market capitalization of $2.5 billion, recently executed a series of stock transactions, ...

It isn’t just artificial intelligence. Chinese biotech companies are now developing drugs faster and cheaper than their US ...

The Mexican president pushed back against a Justice Department document that suggests possible intervention by US agencies ...

However, we still see areas of weakness in the portfolio, including upcoming patent losses and a highly uncertain pipeline due to the complexities of running CNS trials. Historically, the firm ...

New licensing Guidelines issued by the National Institutes of Health at the end of the Biden Administration could harm ...

IBD Aware, a wearable medical device in development for patients with inflammatory bowel disease, aims to improve disease ...

Yuka Manabe and her team at the Center for Innovative Diagnostics for Infectious Diseases aim to improve global health with ...

Unlike opium, nitazenes and other synthetic opioids can be produced anywhere in the world using precursor chemicals that are often uncontrolled.

Deals, pipeline updates and geopolitical issues drove the conversation at the 2025 JP Morgan Healthcare conference.